CLDN18 is a cell surface membrane protein involved in the formation of tight junctions, and the expression of its CLDN18.2 isoform has been observed in pancreatic, gastric and esophageal tumors.
Propanc Biopharma Inc. has announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy.
Israeli biotech Biolinerx Ltd. will hand off the rights to its stem cell mobilizer, motixafortide, in Asia to China’s Gloria Biosciences Co. Ltd. via an out-licensing deal worth up to $280 million, news that sent stocks soaring nearly 13% on Oct. 31.
Some strategies seek to alter molecular mechanisms that can redirect the programmed death of tumor cells. If you can’t selectively eliminate them or stop their proliferation, ask them to die, but don’t tell any other cells. That is the idea proposed by a group of researchers participating in a Chinese-American collaboration for the design of the new drug N6F11. In a mouse model, the compound caused death by ferroptosis only of cancer cells without altering immune cells.
Israeli biotech Biolinerx Ltd. will hand off the rights to its stem cell mobilizer, motixafortide, in Asia to China’s Gloria Biosciences Co. Ltd. via an out-licensing deal worth up to $280 million, news that sent stocks soaring nearly 13% on Oct. 31.
Duo Oncology Inc. has been awarded a Small Business Technology Transfer grant by the National Cancer Institute (NCI) to support the development of DUO-307, a combination nanomedicine that delivers cytotoxic polymer conjugated gemcitabine (PGEM) and an immune modulating chemokine receptor type 2 antagonist (CCR2a) to tumor tissue.
KRAS is a GTP-binding protein involved in cell growth control that requires post-translational farnesylation to be active. KRAS G12D mutations are mostly associated with pancreatic, colorectal and non-small-cell lung cancers and occur less commonly in other cancers. There are currently no therapies approved to specifically target this mutation.
